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Drug discovery FAQs: workflows for
answering multidomain drug discovery
questions
Christine Chichester1,5, christine.chichester@isb-sib.ch, Daniela Digles2,5, Ronald Siebes3,
Antonis Loizou3, Paul Groth3 and Lee Harland4
Modern data-driven drug discovery requires integrated resources to support decision-making and enable
new discoveries. The Open PHACTS Discovery Platform (http://dev.openphacts.org) was built to address
this requirement by focusing on drug discovery questions that are of high priority to the pharmaceutical
industry. Although complex, most of these frequently asked questions (FAQs) revolve around the
combination of data concerning compounds, targets, pathways and diseases. Computational drug
discovery using workflow tools and the integrated resources of Open PHACTS can deliver answers to
most of these questions. Here, we report on a selection of workflows used for solving these use cases and
discuss some of the research challenges. The workflows are accessible online from myExperiment
(http://www.myexperiment.org) and are available for reuse by the scientific community.
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In recent years, there has been an explosion in
the amount of chemical and biological infor-
mation available. Various databases are dou-
bling in size every 18 months [1] and new
databases are continually being created. If these
databases are to remain as information silos, it
appears that our ability to generate vast
quantities of data, often of varied quality, could
surpass our ability to use these data meaning-
fully. For the pharmaceutical industry, coping
with this data load is crucial for the accurate
validation of potential drug targets. Therefore,
data integration and computational techniques
that facilitate searching through multiple het-
erogeneous data sources and filtering for spe-
cific criteria are key technologies in the drug
discovery pipeline [2].1359-6446/ 2014 The Authors. Published by Elsevier Ltd. This is an o
http://dx.doi.org/10.1016/j.drudis.2014.11.006 The decline in the number of new drugs being
brought to the market by pharmaceutical com-
panies has led to paradigm shifts in the strategies
of the industry toward research and development
[3]. These shifts have occurred throughout the
drug discovery pipeline, from research and de-
velopment to data integration. In the case of data
integration, the model of accumulating all public
domain data in-house to complement proprietary
data independently of other companies is pro-
gressively being replaced by precompetitive
initiatives that outsource the public data inte-
gration task. The Open Pharmacological Concepts
Triple Store (Open PHACTS) Discovery Platform [4]
(http://www.openphacts.org) originally spon-
sored by the Innovative Medicines Initiative
(http://www.imi.europa.eu) is one of these data
integration initiatives. It is distinguished by its usepen access article under the CC BY license (http://creativecommons.org/of semantic technologies and its focus on solving
widely applicable drug discovery use cases.
Previously, Open PHACTS consortium members
published a list of 20 core pharmacology-
centered questions [5], which focused on use
cases needed for specific research activities as
well as for drug discovery in general. The ‘20
queries’ approach is a method that keeps the
focus on the most important features that systems
should support [6]. These core questions com-
prise primarily four concepts that are important in
pharmacological research: compound, target,
pathway and disease. The questions provided
model scenarios that drove the data selection and
development processes required for integration
of a diverse set of public domain databases. After
the public release of the Open PHACTS Discovery
Platform [4], we were interested in revisiting theselicenses/by/3.0/).
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a The API definition in full can be found at http://
dev.openphacts.org.
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how the system can be used to answer the
prioritized questions efficiently. To do so, we used
the platform in conjunction with the KNIME [7]
computational workflow environment, which is
commonly used in drug discovery.
A workflow approach
Analysis and hypothesis generation for drug
discovery projects requires assembly, overlay
and comparison of data from many sources [8],
which is ultimately made possible by the use of
shared identifiers and common semantics. Sci-
entific workflows are typically used to automate
the processing, analysis and management of the
scientific data used by these projects. Most sci-
entific workflow programs, such as KNIME [7],
Taverna [9], or Pipeline Pilot [10], provide a user-
friendly graphical workbench that enables
scientists to create and visualize complex
workflows easily that might comprise dozens of
processing and analytical steps. Furthermore,
many workflows provide mechanisms for tracing
provenance and other methodologies that foster
reproducible science [11,12]. Typically, the
functionality of the workflow components falls
into various categories, such as data transfor-
mation, data preparation and data analysis [13],
and can be both part of the workbench or
provided via web services (as application pro-
gramming interfaces or APIs). As the number
and variety of scientific open data APIs steadily
grows, it is becoming easier for the scientific
workflow community to integrate these APIs in
their workflows [14].
Without the use of these workflow tools,
manual data retrieval methods are typically used
that require considerably more time and effort
because of the complexities of data access. In
most instances, data access and reformatting of
different resources is a nontrivial exercise for
most bench scientists, who are unskilled in
programming languages. In the Open PHACTS
project, we developed KNIME utility nodes that
are set to leverage automatically the desired
content from Open PHACTS web services and
simplify the construction of workflow processes
by realizing faster and more efficient data re-
trieval for answering use case questions.
Easy data retrieval
The Open PHACTS API [15] has been constructed
to assure compatibility between the data re-
trieved and inputs required, which facilitates
workflow construction. Results from API calls can
contain two different types of value that can be
used as queries: (i) resource identifiers denoting
Web resources and (ii) literals denoting, for400 www.drugdiscoverytoday.comexample, chemical depictions, such as SMILES
and InChIs. Most API calls require Web resource
identifiers, known as Universal Resource Identi-
fiers (URIs), which are typically written in the
form of a URL (e.g. http://purl.uniprot.org/uni-
prot/P35968 for VEGFR2 protein) as input. Given
that 13 out of 20 use cases (Table 1) needed a
sequence of at least two different API calls, the
compatibility between results and input greatly
eases the assembly of workflows by reducing the
need to reformat queries. Moreover, the API has
been developed in such a way to return results
for which the chaining of calls is not always
necessary. Seven of the 20 use cases could be
answered directly using only one call to the API.
A brief overview of the Open PHACTS APIa
(Table 2) calls and the data returned from each
call is the only background necessary to
understand the approach used to answer the
use case questions. We mostly relied on two of
the main types of API call: (i) information calls
and (ii) pharmacology calls.
Information calls (target information, com-
pound information, disease information, path-
way information and tissue information) return
results that are specific to a query concept (Table
2). For example, the compound information call
is used for use cases (Q2 and Q4 in Table 1),
where there is a need to retrieve the SMILES
strings. The SMILES then can be used sequen-
tially in the chemical structure search using the
similarity call to find similar compounds. If de-
sired, there are some common utility methods
available from the Open PHACTS API that enable
conversion of chemical depictions into URIs
(chemical structure conversion: SMILES to URL,
InChI to URL, or InChIKey to URL) for use in
subsequent pharmacology calls.
In contrast to the ‘information’ calls, ‘phar-
macology’ calls return results based on an ac-
tivity relation between a target and a compound,
which in turn serves to link them (Fig. 1). Pathway
and disease concepts are directly related to
targets in API calls (pathway information: get
targets, pathways for targets, disease for targets
and targets for disease). This enables them to be
related, in turn, to compounds via the targets
and the pharmacology call. Results from both
the ‘information’ and ‘pharmacology’ calls can be
used directly in subsequent API calls, although
the pharmacology calls are the most frequently
exploited in the workflows to answer the use
cases (18 of the 20 workflows).Answering prioritized use cases
As evaluated by Azzaoui et al. [5], the top 20
pharmaceutical use cases fall into two clusters
based on the concepts present in the questions
(Table 2). Cluster 1 use cases deal primarily with
compound–target concepts, whereas, in addi-
tion to the basic pharmacology, Cluster 2
questions include the added complexity of dis-
ease and pathway concepts as well as text-
mined information from patents and literature.
Correspondingly, to answer the range of use
cases, the Open PHACTS API calls are divided
into groups along the same concept lines (target,
compound, pathway and disease) for data re-
trieval. This configuration facilitates the resolving
of the previously proposed use cases, as well as
enabling any new questions revolving around
the same themes to be answered. The meth-
odology for workflow construction (i.e. the
chaining together of several calls) requires some
understanding of the results returned from the
specific API calls. However, the output of each
call has been designed to return data specifically
formatted to work as input for subsequent API
calls.
Building the workflows for the use cases re-
quired that the concept central to the use case
(target, compound, disease, or pathway) be
identified. Then, to resolve its relations to the
other concepts, it was often necessary to de-
compose the natural language of the use case to
determine the correct flow for the API calls. This
meant that the first concept mentioned in the
original use case text was not necessarily the
starting point for the workflow. To demonstrate
the flow of API calls needed for answering the
use cases, the text of the use cases were slightly
rewritten (Table 1) from the original published
text to align the order of the concepts in the
question with the order of the API calls. The
succession of API calls that were used for each
question is indicated in bold in Table 1. Certain
use cases also needed application of some of the
filtering options, which are available from the
API, to execute the different constraints set out in
each use case (italics in Table 1). These filters can
be used to restrict the results of an API call, for
example to return only pharmacology data for a
certain activity type, such as IC50, to introduce
activity cutoffs, or to return data for a specific
organism only. The filter parameters can accept
several values at once. For example, in Q1, by
using the organism filter with the parameters of
‘Mus musculusjHomo sapiens’, both the mouse
and human data were retrieved simultaneously
using a single API call.
Following this approach, we were able to
answer 16 of the 20 identified use case
Drug Discovery Today  Volume 20, Number 4 April 2015 PERSPECTIVE
TABLE 1
Use case questions and the API calls needed to answer thema
ID Use case question Sequence of API calls with filters used and link to the workflow
Cluster 1 use cases (Q1–Q11): answers require mainly compound–target pharmacology data
Q1 Give me all oxidoreductase inhibitors active <100 nM in human and
mouse
Target class pharmacology (target_organism=Homo sapiensjMus musculus;
minEx-pChembl=7); http://www.myexperiment.org/workflows/4504.html
Q2 For a given compound, what is its predicted secondary
pharmacology?
Compound information>chemical structure search:
similarity>compound adverse events
Q3 Given a target find me all actives against that target, and find and/or
predict the polypharmacology of actives
Target pharmacology (minEx-pChembl=5)>compound pharmacology
(minEx-pChembl=0); http://www.myexperiment.org/workflows/4505.html
Q4 For a given interaction profile, give me similar compounds Compound information>compound information (Batch)>chemical
structure search: similarity (searchOptions.Threshold=0.85)>compound
information; http://www.myexperiment.org/workflows/4516.html
Q5 For molecules that contain substructure X, retrieve all bioactivity data
in serine protease assays
Chemical structure search: substructure>compound pharmacology,
target class members; http://www.myexperiment.org/workflows/
4478.html
Q6 For a specific target family, retrieve all compounds in specific assays Target class pharmacology; http://www.myexperiment.org/workflows/
4506.html
Q7 For a target, give me all active compounds with the relevant assay data Target pharmacology (minEx-pChembl=5); http://www.myexperiment.org/
workflows/4507.html
Q8 Identify all known protein–protein interaction inhibitors Target class pharmacology (target_type=ppi, minEx-pChembl=5); http://
www.myexperiment.org/workflows/4508.html
Q9 For a given compound, give me the interaction profile with targets Compound pharmacology (activity_type=IC50jEC50jAC50jKijKdjPotency);
http://www.myexperiment.org/workflows/4509.html
Q10 For a given compound, summarize all similar compounds and their
activities
Chemical structure search: similarity (searchOptions.SimilarityType=0;
searchOptions.Threshold=0.80)>compound pharmacology
(activity_type=IC50jEC50jAC50jKijKdjPotency); http://
www.myexperiment.org/workflows/4510.html
Q11 Retrieve all data for a given list of compounds depicted by their
chemical structure (SMILES) with options to match stereochemistry
Chemical structure search: exact
(searchOptions.MatchType=2)>compound pharmacology, compound
information, compound classifications (tree=chebi); http://
www.myexperiment.org/workflows/4511.html
Cluster 2 use cases (Q12–Q20): answers requiring pharmacology plus disease, pathway and text-mining data
Q12 For a given compound, which of its targets have been patented in the
context of a disease?
Compound pharmacology>patents calls>disease for target
Q13 For disease X, which targets have ligands in different stages of the
development process with publications and/or patents describing
these compounds?
Targets for disease>target pharmacology (minEx-pChembl=5), target
information>patents calls
Q14 Target druggability: compounds directed against target X have what
indications?
Target pharmacology (minEx-pChembl=5)>indications for
compounds>patent calls>disease for targets
Which new targets have appeared recently in the patent literature for
a disease?
Q15 Which chemical series have been shown to be active against target X? Classification of compounds for target (minEx-pChembl=5)
Which new targets have been associated with disease Y? Associations for disease
Which companies are working on target X or disease Y? Competitive Intelligence data not available; http://www.myexperiment.org/
workflows/4512.html
Q16 Targets in Parkinson’s disease or Alzheimer’s disease are activated by
which compounds?
Target for disease>target pharmacology (minEx-pChembl=5); http://
www.myexperiment.org/workflows/4513.html
Q17 For my specific target, which active compounds have been reported in
the literature?
Target pharmacology (minEx-pChembl=5); http://www.myexperiment.org/
workflows/4507.html
Q18 For pathway X, find compounds that agonize targets assayed in only
functional assays with potency <1 MM
Pathway information: get targets>target pharmacology
(activity_type=Potency, max-activity_value=1000, activity_unit=nanomolar);
http://www.myexperiment.org/workflows/4514.html
Q19 For the targets in a given pathway, retrieve the compounds that are
active with more than one target
Pathway information: get targets>target pharmacology (minEx-
pChembl=5); http://www.myexperiment.org/workflows/4515.html
Q20 For a given disease, retrieve all targets in the pathway and all active
compounds hitting those targets
Targets for disease>target pharmacology (minEx-pChembl=5); http://
www.myexperiment.org/workflows/4513.html
a Priority use case questions and workflow sequence of API calls for retrieving answers. Bold text indicates the Open PHACTS API calls and the sequence of calls that were used to retrieve
the data to answer the questions. Filtering parameters (in italics) indicate the values used with the API calls to answer the question. Bold italic text indicates an API call that is not yet
realized. All workflows with example queries have been deposited to myExperiment [21] and the link to the workflow is given.
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periment.org/groups/1125.html) and KNIME
nodes (https://github.com/openphacts/OPS-
Knime) are available for reuse by others, from
the Open PHACTS group on myExperiment(http://www.myexperiment.org; tagged with
‘drug discovery faq’ and ‘open phacts’) and
the GitHub OPS-KNIME repository (https://
github.com/openphacts/OPS-Knime), respec-
tively.Workflow construction challenges
From a close reading of the use cases, it is
obvious that there are expressions that can be
interpreted in more than one way, as well as
uncertainty in the meaning of terms. Ambiguitywww.drugdiscoverytoday.com 401
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Pharmacology calls
Target URIs
UniProt
ChEMBL
EntrezGene
PDB…
Compound URIs
ChemSpider
DrugBank
ChEMBL
PubChem
Wikipedia…
Target information
Pathways for target
Diseases for target
Tissues for proteins
Target class members
Compound information
Pathways for compound
Compound class members
Input for API calls
Results
Compound URIs + activity value + Target URIs
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FIGURE 1
Schematic of the input and main results from the Open PHACTS Pharmacology API calls and the available subsequent application programming interface (API)
calls. The Open PHACTS API calls allow several different identifiers (in the format of an URI) as input. The figure shows examples of different compound and target
identifiers that can be used for input in the pharmacology calls. The main results from the pharmacology API calls are again compound and target URIs, which are
connected by their reported bioactivity. These URIs can be used directly for several different API calls, as shown.
TABLE 2
A list of Open PHACTS API calls frequently used in workflowsa
Open PHACTS API call Data types Provenance
Target information Target depictions: amino acid sequence, number of residues,
theoretical pI, mass, textual labels
SwissProt, DrugBank
Target annotations: function, interacting proteins, target components,
cellular localization, GO terms, UniProt keywords
SwissProt, Chembl, DrugBank
Drugs specific for target DrugBank
Links to other datasets: GO annotations, Protein Databank SwissProt
Compound information Compound depictions: SMILES, InChI, InChIKey, molecular formula,
textual labels
OPS Chemical Registry
Compound properties: hydrogen bond donors/acceptors, molecular
weight, rule of five violations, rotatable bonds, logP, polar surface area,
melting point
OPS Chemical Registry
Compound annotations: biotransformation, toxicity, protein binding,
description, classification as per drug approval process, drug–drug
interactions
DrugBank
Tissue information Tissue description neXtProt
Links to other data sets (cross-references): foundational model of
anatomy, Brenda tissue ontology, UBERON, medical subject headings
neXtProt
Disease information Disease depictions: textual label DisGeNet
Annotations: disease class DisGeNet
Pathway information Pathway depictions: textual label, pathway organism, pathway
elements
WikiPathways
Annotations: pathway description, pathway ontology terms WikiPathways
Target pharmacology Pharmacology components: target, target textual name, compound ChEMBL
Compound–target activity annotations: published activity type,
published activity value, activity units, pChEMBL value, assay, assay
comment, assay organism, DOI, target type
ChEMBL
Compound pharmacology Pharmacology components: compound, target ChEMBL
Compound–target activity annotations: published activity type,
published activity value, activity units, pChEMBL value, assay, assay
description, assay comment, assay organism, DOI, drug type, drug
generic name
ChEMBL, DrugBank
a The Open PHACTS Information and Pharmacology API calls can return several data types from various different sources. The table lists the API call, the data returned (Data types) and the
sources of the data (Provenance). Although most data returned for a query are optional (i.e. can be missing from the output if no data are available), some information (indicated in bold)
must be available for any result to be returned from the call.
402 www.drugdiscoverytoday.com
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Drug Discovery Today  Volume 20, Number 4 April 2015 PERSPECTIVEis an intrinsic phenomenon in scientific language
and a fundamental property of linguistic ex-
pression, which can cause difficulties when de-
veloping universal workflows. For instance, the
notion of ‘active’ compound depends heavily on
the interpretation of a threshold concentration
at which a compound exerts an effect. There
were six (Q3, Q7, Q16, Q17, Q19 and Q20) use
cases that contained the notion of ‘active’
compounds without specifying a specific activity
threshold, and two use cases that did give
threshold values (Q1 and Q18 with >100 nM and
1 nM, respectively). The pharmacology APIs have
several filtering options, which can be set to
retrieve data corresponding to specific thresh-
olds. For the use cases with unspecified activity
thresholds, in our deposited workflows, we fil-
tered for a pChEMBL value >5 as our determi-
nation of active. pChEMBL is defined as the
log molar IC50, XC50, EC50, AC50, Ki, Kd, or po-
tency. This value permits roughly comparable
measures of half-maximal response concentra-Table creator
Substructure SMILES
Serine protease c
(EC and Che
Substructure s
Table crea
O
N
N
N
O
N
FIGURE 2
Example KNIME workflow for Q5. The workflow for Q5 u
input for the chemical structure search:substructure cal
serine protease class URIs from the ENZYME and ChE
pharmacology results are filtered according to the clas
resulting number of compounds per target are showtion, potency and/or affinity to be compared on
a negative logarithmic scale. For example, an IC50
measurement of 10 MM would have a pChEMBL
value of five [16].
Another difficulty is the ambiguity of phrases,
such as ‘interaction profile’ in Q4. ‘Interaction
profile’ could refer to the interaction profile with
targets as specified in Q9, making Q4 and Q9
very similar. Instead, ‘interaction profile’ was
interpreted as the drug–drug interaction profile,
which can be retrieved from the compound
information API call, to highlight other available
data.
Data quality is always an important concern in
solving domain use cases [17]. Here, certain
questions emphasize the requirement of re-
trieving ‘all’ results (Q6, Q8, Q10, Q11 and Q20).
Clearly, it is possible that not every data point is
available in the integrated data resources and,
therefore, depending on the requirements of the
user, might not produce the expected result.
Data quality ultimately has many dimensions35
Compounds
Coagulation factor X
Thrombin
Plasma kallikrein
Tissue-type plasmino
Urokinase-type plasm
Vitamin K-dependen
Target class
members
Reference
row filter
lass URIs
mbl)
earch
tor
Compound
pharmacology
Co
ses three different Open PHACTS application programm
l. The resulting compounds from this call are passed to th
MBL target classification hierarchies are the input for 
s members to determine the compounds for the serine
n.and, thus, is a complex problem when it comes
to meeting user expectations. For example, in
Q17, retrieving activity results from the ChEMBL
data set implies that they were published, be-
cause the data are primarily assembled from the
literature, although curation issues might cause
discrepancies between the returned result and
user expectations.
Finally, some use cases comprised several
questions, of which not all could be resolved.
Often these questions required data that are out
of the scope of the project or not currently
available from open access data providers. For
example, Q15 has one component that fits the
range of the currently integrated data (targets
for disease), whereas the second part of the use
case is focused on competitive intelligence data,
which is not currently in the system. Answering
Q13 and Q14 requires text mining of literature
and patent data. Although not available cur-
rently, in subsequent releases of the platform
data from SureChEMBL, an open database of the7
1111
 per target
gen activator
inogen activator
t protein C
GroupBy
Interactive table
Interactive table
Activity data
unts for pie chart
Drug Discovery Today 
ing interface (API) calls. A SMILES string is starting
e compound pharmacology call. Concurrently, the
the target class members call. Subsequently, the
 protease type targets. The input structure and the
www.drugdiscoverytoday.com 403
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agents found in patents will be added, which will
enable these use cases to be addressed. More-
over, when the data sources are updated, the
user’s expectations can change and some of the
use cases could have alternate solutions using
new data sources and API calls.
Ontology use cases
The prioritized use cases are mainly focused on
the use of the pharmacology API calls. However,
there are additional API calls (compound clas-
sifications, compound class members, classifi-
cation of targets for compound, compound class
pharmacology, target classifications, target class
members, classification of compounds for target,
target class pharmacology and hierarchy calls),
used in only four of the 20 uses cases, that take
advantage of searching in organized hierarchies
or ontologies to find relevant information. Hav-
ing a variety of ontologies available for explo-
ration can be useful for drug discovery use cases
because they offer a formal description of the
relations between concepts in a specific domain.
Gene Ontology (GO) [18] is arguably the most
widely used ontology in life sciences. It struc-
tures information about biological processes,
molecular functions and cellular components in
a loosely hierarchical fashion. Structurally similar
to GO, ChEBI [19] provides an ontology of
chemical compounds of biological interest
based on relations between chemical structural
and functional features. The ChEMBL Target
Classification scheme and the ENZYME classifi-
cation (EC) [20] are also available in API calls and
organize protein concepts in terms of parent–
child hierarchies. The use of these ontologies to
retrieve knowledge concerning sets of concepts
within a domain is demonstrated in Q5 (Fig. 2).
Here, we used two different hierarchies, the
ChEMBL Target Classification and the EC, to
retrieve the class of serine proteases as orga-
nized by two different authorities. The Q5
workflow is executed as follows; first, all phar-
macology data corresponding to the specific
substructure are retrieved using the sequence of
chemical structure search:substructure followed
by the compound pharmacology call. These data
are then filtered for targets that are members of
the serine protease class of the ChEMBL classi-
fication and the EC as retrieved with the target
class members API call. The outcome is activities
for six different serine protease targets. In a
hypothetical use case, GO could be used in a
similar workflow, for instance to obtain all
compounds that are pharmacologically active
against proteins known to be involved in pro-
cesses such as cell replication or immune system404 www.drugdiscoverytoday.comresponse. These ontology resources provide a
knowledge representation of a domain from a
specific viewpoint in a machine usable format. Of
course, what is specified in any ontology is not
the absolute truth, but is only reflective of the
available state of knowledge as documented by
the data provider. As such, the availability of
several different ontologies can offer another
approach for information analysis, knowledge
and intellectual property creation.
Concluding remarks
From the perspective of a researcher, the ideal
data infrastructure should make it easy to search
across different data sources containing data
about drugs, clinical trials, diseases, pharma-
ceutical companies and so on, to identify novel
and meaningful correlations. The Open PHACTS
Discovery Platform provides this capability;
leveraging public domain data, a full corpus of
computational workflows has been developed
that answers most of the high-priority use case
questions from the pharmaceutical industry.
Even though there are many ways to gather the
data necessary to answer the use cases, the aim
of the Open PHACTS Discovery Platform is to
make these complex analyses simpler and faster
to perform. For instance, identifier schemes do
not need to be reconciled because the platform
supports all the main inputs (SMILES, InChI,
UniProt, EntrezGene, among others) and the
data structures of the different integrated data
sets are homogenized into a single API output.
This highly available and reliable API generates
output that also encourages application devel-
opers to build real-world applications (https://
dev.openphacts.org/apps). Finally, the availabil-
ity of workflow components (KNIME and Pipeline
Pilot) lessens the load for busy scientists, be-
cause they do not need to worry about (i)
installing local copies of the various databases;
(ii) learning to write code or (iii) performing hefty
Excel manipulations to address the questions
they most frequently ask.
With the addition of new data sets, such as the
information related to adverse events and
patents, the relations between the concepts
already available will be expanded to provide
new paths for traversing the knowledge net-
work. Concretely, the integration of these new
data sets will enable all 20 use cases to be
completely addressed. Furthermore, new and
more elaborate workflows for computational
drug discovery can be implemented. The use of
ontologies is also a key step forward for struc-
turing drug discovery data in a way that helps
scientists to understand the relations that
exist between concepts in specialized areasof interest, as well as to provide different per-
spectives on the relevant domains that should
be more fully exploited.
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